Managing Benzodiazepine Withdrawal Itching During Tapering

Key Takeaways

• Itching is a recognized benzodiazepine withdrawal symptom, and it is managed by adjusting the pace of the taper and protecting the skin, never by stopping the medication.
• The itch usually comes from oversensitive nerves rather than from a problem in the skin itself, which is why scratching does not settle it for long.
• A crawling feeling, as if insects were on the skin, is not uncommon in withdrawal and is often worse at night.
• The itch tends to appear a few days after a dose reduction, peak, and then fade as the nervous system settles at the new dose.
• When the itch arrives with every dose reduction, the reductions are too big or too close together, and the pace should be discussed with the prescriber.
• Cool compresses, lukewarm showers, fragrance-free moisturizer, loose cotton clothing, and short fingernails protect the skin while the nerves settle.
• Get emergency care for a rash with fever, for hives with swelling of the lips, tongue, or throat, for trouble breathing, or for blistering or peeling skin.
• Have a doctor look at broken skin that seems infected, a rash that spreads, or itching with yellowing of the eyes or skin.

Is itching a real benzodiazepine withdrawal symptom?

Yes, and it is a recognized one. Chapter III of the Ashton Manual, Professor C. Heather Ashton’s guide to benzodiazepine withdrawal at benzo.org.uk, lists “skin rashes, itching” in its Table 1 of withdrawal symptoms. In the same chapter she describes a sensory hypersensitivity in which the skin and scalp become so sensitive that it feels as if insects are crawling over them.

Patients describe it in a few recurring ways. An itch with nothing to see, a prickle or crawl that moves from the arms to the scalp to the back, a burning patch that comes and goes, and all of it worse at night. Scratching does not settle it for long, because the problem is not on the skin.

Most people who reach this page took their medication exactly as prescribed, often for years, and the itching arrived only when the dose started to fall. That is physical dependence, a condition the medication itself created, and dependence is not addiction. The right response is a gradual, medically supervised taper, not a treatment model built for a different problem.

Why does a calming drug leave the skin on edge when the dose falls?

Benzodiazepines work by enhancing gamma-aminobutyric acid (GABA), the brain’s main quieting signal, and Professor Ashton explains in Chapter I of the Manual that GABA tells the nerve cells it reaches to slow down or stop firing. Taken daily for months, that extra quieting becomes part of the nervous system’s settings, and the brain compensates by turning its own alerting systems up. When the dose falls, the compensation runs unopposed for a while, and the senses run hot.

Think of a smoke detector with its sensitivity turned all the way up. While no analogy is perfect, this one is close: steam from a kettle sets it off, and nothing in the house is burning. Withdrawal itching is the skin’s nerves reporting a fire that is not there, and the report fades as the sensitivity comes back down.

Professor Ashton adds a detail that helps people tell withdrawal from ordinary worry. The feeling of insects crawling on the skin, she writes, is not uncommon in benzodiazepine withdrawal but unusual in anxiety states. So, a crawling itch that arrived with a dose reduction is more likely the taper than the nerves of the person doing it.

Z-drugs behave the same way. The Manual notes in Chapter II that zolpidem (Ambien), zopiclone, and zaleplon (Sonata) have the same actions as benzodiazepines, so the same itch can appear in a z-drug taper and the same rules apply.

A few patients get more than an itch: flushing, hives, or reactions that look like a food allergy with negative allergy tests. Whether histamine is behind that is not settled, and the evidence is thin. That question has its own article on this site, on histamine and allergy-like symptoms in benzodiazepine withdrawal.

A flare of itching means hold or slow the taper, never stop.

Withdrawal itching tracks the pace of the taper more than anything else. It tends to appear a few days after a reduction, peak, and then fade as the nervous system settles at the new dose, and when it arrives with every step, the step was too big or came too soon. The itch is information about the pace.

The Ashton Manual’s answer, in Chapter II, is to reduce by up to one tenth of the dose at each step and to let the patient set the speed. Professor Ashton writes that the best judge is usually the patient, who must be in control and proceed at a comfortable pace, and that a person can stop at a given dose for a few weeks if necessary while trying to avoid going backwards. In Dr. Leeds’ practice, a small updose to the last steady dose, agreed with the prescriber, is also a legitimate decision, not a failure. A flare is often met by a short hold at the current dose and a smaller next step, though everybody is different and some patients do better keeping a steady pace.

The Maudsley Deprescribing Guidelines describe the same idea with a different shape: hyperbolic reductions, in which each step is a fraction of the current dose rather than of the starting dose, so the steps shrink as the dose falls. The lowest doses get the smallest cuts, because that is where the nervous system notices each change the most.

What a flare never means is that the drug should be stopped. The United States Food and Drug Administration (FDA) updated the boxed warning on every benzodiazepine in September 2020 to state that physical dependence can occur within days to weeks even when the drug is taken as prescribed, and that stopping abruptly or reducing the dose too quickly can cause withdrawal reactions, including seizures, which can be life-threatening. Call emergency services for a seizure or any medical emergency.

The Manual does allow one exception, noting in Chapter II that triazolam (Halcion), with a half-life of about two hours, can be stopped abruptly without substitution of a long-acting drug. Dr. Leeds tapers triazolam like any other benzodiazepine, consistent with the 2020 label update, and an itch that came from a small reduction is a poor argument for making a large one.

Simple skin care helps more than strong drugs.

Comfort measures do most of the work while the nerves settle. A cool compress on the worst patch, lukewarm rather than hot showers, a fragrance-free moisturizer after bathing, loose cotton clothing, and short fingernails cover most of it. The goal is to keep the skin intact, because scratched, broken skin invites infection, the one complication that turns a nuisance into a real skin problem.

Withdrawal itching is a nerve signal, not an inflamed skin disease. The drugs made for inflamed skin are aimed at a different problem, and each one adds its own risks to a nervous system that is already sensitive. The Manual lists the symptom without prescribing anything for it, and that is the right instinct.

Whether any medication for the itch belongs in a particular taper, and for how long, is a question for the prescriber who knows the whole taper, decided for that patient and never as a default.

When is a rash not withdrawal, and when is it an emergency?

The Manual lists rashes as well as itching, so a mild, passing rash can be part of withdrawal. Certain patterns are not, and they should never be waited out. A rash with a fever, hives with swelling of the lips, tongue, or throat or any trouble breathing, or blistering or peeling skin needs emergency care, not a taper adjustment. A rash that began within days of starting any new medication needs a same-day call to the prescriber, and emergency care if any of those signs come with it.

Short of an emergency, some itching still deserves a visit. Broken skin that looks infected, a rash that spreads or persists through a hold, itching with yellowing of the eyes or skin, or an itch that does not settle at all after the taper has been slowed should be examined, because a separate cause may be sitting underneath. Withdrawal does not protect anyone from ordinary skin disease, and a taper doctor would rather look than guess.

How Dr. Leeds handles itching in a supervised taper.

Dr. Leeds is an osteopathic physician and deprescribing specialist in Fort Lauderdale, Florida, and his practice focuses on medically supervised tapering off of benzodiazepines and z-drug sleeping pills for patients in Florida, with one physician working directly with each patient. Itching is treated in that practice as what it is, a report on the pace. A change of pace comes first, a short hold or a smaller step for some patients and a steady pace for others, because everybody is different, and no one is pushed through a reduction they cannot tolerate.

For patients on a short-acting drug, he uses the crossover taper the Ashton Manual describes, moving to diazepam where it helps, because a long-acting drug gives a smooth, gradual fall in blood level and small, even steps. He shapes the reductions hyperbolically, per the Maudsley Deprescribing Guidelines, so the steps get smaller as the dose gets lower. A taper of this kind takes months, sometimes longer, and its length is set by the patient’s nervous system, not a calendar.

The patient directs it. Before each reduction the risks are stated first, a flare of itching among them, and the patient may decline a step, ask for a longer hold, or set the next reduction smaller. If the pace is too fast, the doctor’s job is to say so and slow it, and if it is comfortably slow, patient and doctor may agree to go a little faster, as tolerated.

Fortunately, this symptom is one of the ones that leaves. The skin was never the problem, and it does not need to be fixed. It needs time, and a pace it can keep.

Dr. Leeds’ practice offers medically supervised benzodiazepine and z-drug tapering to patients in Florida, adapted to each person and paced by the patient. Anyone whose skin has started to itch or crawl partway through a taper, or who is planning one, is welcome to ask about supervised care. Contact the office.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.